Person Overview

Update
Primary:
Scientific Co-Founder at Juno Therapeutics
Education:
SUNY College at Oswego, SUNY College at Oswego
Location:
New York

Detailed Description

Update

Dr Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale-New Haven Hospital, and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC). Currently, Dr Brentjens is an associate member on the faculty at MSKCC and an attending physician on the Leukemia Service.

As a medical oncology fellow at MSKCC, Dr Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs).

Following completion of his medical oncology training, Dr Brentjens became the principle investigator of his own laboratory. As a PI, Dr Brentjens successfully translated these studies to the clinical setting, treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL).

Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T cells” currently being translated to the clinical setting as second generation CAR modified T cell clinical trials. Additionally, work in the Brentjens’ lab has expanded this CAR technology to target additional tumor antigens.

Experience (1)

Update

Education (2)

Update